entertainment -WSS

entertainment

author：comprehensive 2025-09-06 02:15:07 - browse：2587

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： YouTube cracks down on misinformation on cancer treatment

focus

WSS

Mark Cuban is blaming the wrong people for high drug costs

Idaho college killings prosecutors challenge defense's grand jury claims

Judge sides with young activists in first

Immunocompromised patients offer clues on chronic Covid

Treatments for cramps don't cut it. Why aren't there better options?

Biden administration begins canceling student loan debt for 804,000 borrowers

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Cancer drug shortages should be causing more outrage

Indictment alleges Trump's ex

Wildfire smoke exposes gaps in outdoor worker protections

Microsoft launches AI tool for clinical documentation through Epic

Peter Hotez and the public health issue of online harassment

Senators push IRS to launch nonprofit hospital probe

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Sports medicine is finally prioritizing gender equality

Illumina slashes 2023 revenue projections yet again

hotspot

Inaction leaves children at risk from dangerous chemotherapy drug

To bolster infectious disease surveillance, genomics powerhouses team up

Biden administration begins canceling student loan debt for 804,000 borrowers

Update the Apgar Score to remove skin color

There's an unseen cost to disruptive road

Biden administration begins canceling student loan debt for 804,000 borrowers

focus

Wikipedia

knowledge

leisure time